D. Esseltine

发表

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

J. Leonard, K. Kolibaba, J. Reeves, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

J. Crowley, G. Mulligan, D. Esseltine, 2016, Cancer cell.

Clinical trials with blocked ricin immunotoxins.

D. Esseltine, T. Lynch, J. Lambert, 1998, Current topics in microbiology and immunology.

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Hartmut Goldschmidt, Mario Boccadoro, David Irwin, 2005, The New England journal of medicine.

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Anthony Boral, Paul Richardson, Yongsheng Huang, 2006, Blood.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bin Jiang, Ofer Shpilberg, D. Esseltine, 2008, The New England journal of medicine.

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

D. Esseltine, K. Anderson, P. Sonneveld, 2017, British journal of haematology.

Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia

J. Byrd, J. Gribben, I. Flinn, 2006, Cancer.

Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

D. Esseltine, H. van de Velde, P. Moreau, 2015, Haematologica.

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

R. Neuwirth, D. Esseltine, K. Venkatakrishnan, 2012, Clinical Cancer Research.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

D. Esseltine, A. Ivanova, B. Mitchell, 2005, Blood.

Second-Generation Proteasome Inhibitors

D. Esseltine, K. Anderson, L. Dick, 2011 .

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone.

D. Esseltine, M. Dimopoulos, J. Miguel, 2010, Blood.

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.

D. Esseltine, B. Pégourié, B. Grosbois, 2011, Blood.

c‐MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide‐dexamethasone in myeloma

D. Esseltine, P. Ganly, J. Keats, 2020, European journal of haematology.

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

D. Esseltine, M. Terol, F. Prósper, 2004 .

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.

J. Reeves, I. Flinn, R. Neuwirth, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

D. Esseltine, P. Richardson, J. S. San Miguel, 2012, European journal of haematology.

Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients

R. Neuwirth, D. Esseltine, P. Sonneveld, 2007, American journal of hematology/oncology.

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

D. Esseltine, P. Wen, S. Lonial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I T rial o f t he P roteasome I nhibitor P S-341 i n P atients With R efractory H ematologic M alignancies

D. Esseltine, S. Soignet, P. Elliott, 2002 .

Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: subgroup analysis of a randomized phase 3 trial

D. Esseltine, B. Coiffier, P. Zinzani, 2012, Journal of Hematology & Oncology.

patients with relapsed systemic AL amyloidosis : results of a phase 1 / 2 Efficacy and safety of once-weekly and twice-weekly bortezomib

D. Esseltine, D. Reece, G. Merlini, 2011 .

Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

D. Esseltine, H. van de Velde, D. Reece, 2011, Blood.

Characterization of haematological parameters with bortezomib–melphalan–prednisone versus melphalan–prednisone in newly diagnosed myeloma, with evaluation of long‐term outcomes and risk of thromboembolic events with use of erythropoiesis‐stimulating agents: analysis of the VISTA trial

D. Esseltine, M. Dimopoulos, P. Richardson, 2011, British journal of haematology.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

D. Esseltine, F. Prósper, M. Terol, 2008, Haematologica.

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.

D. Esseltine, H. van de Velde, P. Moreau, 2011, The Lancet. Oncology.

A Multicenter Phase II Trial of Bortezomib in Patients with Previously Untreated Multiple Myeloma: Efficacy with Manageable Toxicity in Patients with Unexpectedly High Rates of Baseline Peripheral Neuropathy.

D. Esseltine, P. Wen, K. Anderson, 2005 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Results of a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

A Phase II Study of Bortezomib (Velcade ®), Cyclophosphamide (Cytoxan®), Thalidomide (Thalomid®) and Dexamethasone as First-Line Therapy for Multiple Myeloma

D. Esseltine, S. Jagannath, D. Vesole, 2007 .

Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Lenalidomide, Bortezomib, and Dexamethasone (Rev/Vel/Dex) as Front-Line Therapy for Patients with Multiple Myeloma (MM): Preliminary Results of a Phase 1/2 Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2007 .

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

D. Esseltine, P. Ganly, P. Richardson, 2017, Blood.

Phase II study of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with relapsed or relapsed and refractory multiple myeloma (MM)

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

relapsed, refractory multiple myeloma Clinical factors predictive of outcome with bortezomib in patients with

D. Esseltine, B. Barlogie, S. Jagannath, 2013 .

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

R. Neuwirth, D. Esseltine, H. Goldschmidt, 2008, Leukemia.

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

Bortezomib in recurrent and/or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials

D. Esseltine, H. van de Velde, A. Regnault, 2016, British journal of haematology.

Herpes zoster complicating bortezomib therapy of relapsed/refractory indolent B-cell and mantle cell lymphoma: an analysis of two phase II trials

R. Neuwirth, D. Esseltine, S. de Vos, 2013, Leukemia & lymphoma.

Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?

D. Esseltine, J. Teruya-Feldstein, M. Gonen, 2006, British journal of haematology.

Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.

D. Esseltine, D. Agus, D. Petrylak, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.

W. Wilson, J. Gribben, D. Esseltine, 2000, Cancer journal.

Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180.

D. Esseltine, S. Treon, I. Ghobrial, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial.

D. Esseltine, M. Mohty, G. Marit, 2006 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

patients with newly diagnosed multiple myeloma Lenalidomide, bortezomib, and dexamethasone combination therapy in

D. Esseltine, S. Jagannath, A. Jakubowiak, 2012 .

study patients with relapsed systemic AL amyloidosis: results of a phase 1/2 Efficacy and safety of once-weekly and twice-weekly bortezomib in

D. Esseltine, D. Reece, G. Merlini, 2011 .

Bortezomib, doxorubicin and dexamethasone (PAD) front‐line treatment of multiple myeloma: updated results after long‐term follow‐up

D. Esseltine, J. Cavenagh, N. Curry, 2008, British journal of haematology.

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

D. Esseltine, B. Barlogie, S. Jagannath, 2006, Haematologica.

Phase I Trials

D. Esseltine, D. Schenkein, 2004 .

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model‐Based Support for Body Surface Area‐Based Dosing Over the 2‐ to 16‐Year Age Range

R. Neuwirth, K. Suryanarayan, D. Esseltine, 2017, Journal of clinical pharmacology.

Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

High Response Rates and Encouraging Time-to-Event Data with Lenalidomide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Final Results of a Phase I/II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009 .

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2012, Clinical Pharmacokinetics.

with multiple myeloma: results of a multicenter phase 1/2 study Bortezomib plus melphalan and prednisone in elderly untreated patients

D. Esseltine, A. Oriol, J. Bargay, 2011 .

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.

D. Esseltine, H. Goldschmidt, P. Sonneveld, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Blood.

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

D. Esseltine, P. Sonneveld, P. Richardson, 2008, British journal of haematology.

The Cost-Effectiveness of Bortezomib Plus Melphalan and Prednisone Versus Lenalidomide Plus Melphalan and Prednisone with Continuous Lenalidomide Maintenance Treatment for the Initial Treatment of Multiple Myeloma In the United States

D. Esseltine, M. Duh, A. Cakana, 2010 .

The Cost-Effectiveness of Bortezomib for the Initial Treatment of Multiple Myeloma in the United States.

D. Esseltine, L. Garrison, M. Duh, 2009 .

A Budget Impact Model Comparing Resource Utilization of Four Approved Therapies for Multiple Myeloma (MM) in the US.

D. Esseltine, J. L. Marantz, D. Fullerton, 2007 .

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

D. Esseltine, H. Einsele, S. Lonial, 2017, British journal of haematology.

Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

D. Esseltine, J. Miguel, A. Oriol, 2016, Annals of Hematology.

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

D. Esseltine, B. Barlogie, P. Wen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osteogenic sarcoma following treatment with megavoltage radiation and chemotherapy for bone tumors in children.

D. Esseltine, C. Freeman, L. Chevalier, 1980, Medical and pediatric oncology.

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

R. Millikan, D. Esseltine, P. Elliott, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retinoblastoma: The case for radiotherapy and for adjuvant chemotherapy

D. Esseltine, C. Freeman, C. Freeman, 1980, Cancer.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Bin Li, Matthew Schu, R. Neuwirth, 2014, Blood.

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

G. Mulligan, D. Esseltine, P. Sonneveld, 2012, Blood.

Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2007, British journal of haematology.

Bortezomib-induced tumor lysis syndrome in multiple myeloma.

D. Esseltine, S. Singhal, J. Mehta, 2006, Clinical lymphoma & myeloma.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bart Barlogie, Gordan Srkalovic, David Irwin, 2003, The New England journal of medicine.

An historic perspective of proteasome inhibition.

G. Mulligan, D. Esseltine, 2012, Seminars in hematology.

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2005, Cancer.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010, Blood.

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose‐modification guideline

D. Esseltine, H. Goldschmidt, P. Wen, 2009, British journal of haematology.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Beverly S Mitchell, D. Esseltine, S. Soignet, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study

D. Esseltine, Huyuan Yang, A. Hui, 2015, Journal of Hematology & Oncology.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

D. Esseltine, D. Reece, V. Kukreti, 2014, Blood.

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug‐Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

D. Esseltine, K. Venkatakrishnan, J. Nemunaitis, 2017, Journal of clinical pharmacology.

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

D. Esseltine, A. Hui, K. Venkatakrishnan, 2015, British journal of clinical pharmacology.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

A. Zelenetz, D. Esseltine, M. Stubblefield, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Franziska Michor, Michael H. Tomasson, Irene M. Ghobrial, 2016, Clinical Cancer Research.

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Anthony Boral, Hartmut Goldschmidt, Mario Boccadoro, 2007, Blood.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

D. Esseltine, S. de Vos, B. Coiffier, 2011, The Lancet. Oncology.

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

D. Esseltine, J. Stec, G. Hortobagyi, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

D. Esseltine, S. Jagannath, N. Munshi, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

D. Esseltine, A. Palumbo, P. Richardson, 2014, Haematologica.

PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

D. Esseltine, J. Stec, J. Cavenagh, 2005, British journal of haematology.

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

D. Esseltine, P. Sonneveld, A. Jakubowiak, 2008, British journal of haematology.

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.

D. Esseltine, F. Prósper, M. Terol, 2006, Blood.

Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis.

D. Esseltine, D. Dubois, A. Bhakar, 2007, Journal of clinical epidemiology.

Quantifying The Risk Of Heart Failure Associated With Proteasome Inhibition: A Retrospective Analysis Of Heart Failure Reported In Phase 2 and Phase 3 Studies Of Bortezomib (Btz) In Multiple Myeloma (MM)

D. Esseltine, P. Sonneveld, S. Lonial, 2013 .

Anti‐B4‐blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma

D. Esseltine, L. Nadler, P. Fidias, 1998, British journal of haematology.

Response to bortezomib and activation of osteoblasts in multiple myeloma.

D. Esseltine, G. Tricot, M. Zangari, 2006, Clinical lymphoma & myeloma.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan–prednisone vs. melphalan–prednisone in the phase III VISTA trial in multiple myeloma

D. Esseltine, H. Goldschmidt, M. Dimopoulos, 2011, European journal of haematology.

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

D. Esseltine, F. Zhan, G. Tricot, 2011, Haematologica.

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

D. Esseltine, B. Barlogie, P. Sonneveld, 2005, British journal of haematology.

melphalan-prednisone versus melphalan-prednisone analysis of the phase 3 VISTA study of bortezomib plus therapy: diagnosed multiple myeloma patients treated with nonintensive Superior outcomes associated with complete response in newly

D. Esseltine, A. Palumbo, J. Miguel, 2012 .

Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma

D. Esseltine, L. Fink, M. Zangari, 2008, Haematologica.

Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011, European journal of haematology.

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up

D. Esseltine, S. Jagannath, A. Jakubowiak, 2010 .

Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.

D. Esseltine, J. Ritz, T. Lynch, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Descriptive and prognostic value of patient-reported outcomes: the bortezomib experience in relapsed and refractory multiple myeloma.

Muriel Viala, D. Esseltine, D. Dubois, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged therapy with bortezomib plus melphalan-prednisone (vmp) results in improved quality and duration of response in the phase iii vista study in previously untreated multiple myeloma (mm)

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Encouraging Response Rates and Tolerability with Correlation of Outcome and Adverse Cytogenetics in a Phase II Study.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2008 .

Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Newly Diagnosed Multiple Myeloma

D. Esseltine, M. Dimopoulos, A. Palumbo, 2008 .

Reduced Dose PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

D. Esseltine, J. Cavenagh, D. Schenkein, 2005 .

Continued Overall Survival Benefit After 5 Years' Follow-up with Bortezomib-Melphalan-Prednisone (VMP) Versus Melphalan-Prednisone (MP) in Patients with Previously Untreated Multiple Myeloma, and No Increased Risk of Second Primary Malignancies: Final Results of the Phase 3 VISTA Trial

D. Esseltine, M. Dimopoulos, A. Palumbo, 2011 .

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

D. Esseltine, K. Venkatakrishnan, P. Moreau, 2011 .

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

D. Esseltine, P. Ganly, N. Munshi, 2016 .

Randomized Phase 2 Open-Label Study of R-CHOP ± Bortezomib in Patients (Pts) With Untreated Non-Germinal Center B-Cell-like (Non-GCB) Subtype Diffuse Large Cell Lymphoma (DLBCL): Results From the Pyramid Trial (NCT00931918).

J. Leonard, K. Kolibaba, J. Reeves, 2015, Clinical advances in hematology & oncology : H&O.

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

D. Esseltine, P. Wen, S. Lonial, 2004 .

Use of Patient-Reported Outcomes (PROs) to Assess Prognosis, Toxicity, and Response: The Bortezomib Experience in Relapsed and Refractory Multiple Myeloma (MM).

D. Esseltine, D. Dubois, C. Loge, 2004 .

193Normal hematopoietic stem cell function in mice following treatment with bortezomib

D. Esseltine, D. Schenkein, N. Weich, 2003 .

The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.

D. Esseltine, B. Barlogie, P. Sonneveld, 2005 .

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

D. Esseltine, L. Carey, A. Ivanova, 2008, Cancer Chemotherapy and Pharmacology.

Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma (MM): Final results of a multicenter phase I/II study.

D. Esseltine, K. Anderson, S. Jagannath, 2010 .

Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.

D. Esseltine, P. Ganly, J. Miguel, 2016 .

A268 Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma

M. Kaminski, D. Esseltine, K. Griffith, 2009 .

Bortezomib Plus Melphalan–Prednisone Continues to Demonstrate a Survival Benefit Vs Melphalan–Prednisone in the Phase III VISTA Trial in Previously Untreated Multiple Myeloma After 3 Years' Follow-up and Extensive Subsequent Therapy Use.

D. Esseltine, M. Dimopoulos, A. Palumbo, 2009 .

Multiple Myeloma: Patient out-of-Pocket Costs and Health Care Utilization.

D. Esseltine, H. Henk, B. Pinsky, 2009 .

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

D. Esseltine, B. Barlogie, S. Jagannath, 2004, British journal of haematology.

Metastatic Adenoid Cystic Carcinoma of Salivary Glands: Case Reports and Review of the Literature.

Horton, D. Esseltine, J. Ruckdeschel, 1996, Cancer control : journal of the Moffitt Cancer Center.

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

M. Kaminski, D. Esseltine, K. Griffith, 2011, Blood.

Prospective Evaluation of the Bone Anabolic Effect of Bortezomib in Relapsed Multiple Myeloma (MM) Patients.

Joshua D. Dilley, D. Esseltine, B. Barlogie, 2007 .

Bortezomib in Combination with High-Dose Dexamethasone (HD dex) and Erythropoietin (EPO) Does Not Result in an Increased Risk of Thromboembolic Complications.

D. Esseltine, P. Sonneveld, S. Jagannath, 2006 .

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

D. Esseltine, S. Jagannath, A. Jakubowiak, 2014, Blood.

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

G. Mulligan, D. Esseltine, S. de Vos, 2013, Clinical Cancer Research.

PAD combination therapy (PS-341/bortezomib, adriamycin and dexamethasone) for previously untreated patients with multiple myeloma.

D. Esseltine, J. Stec, J. Cavenagh, 2004 .

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

D. Esseltine, A. Palumbo, P. Richardson, 2014, Haematologica.

Switching from body surface area-based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis.

D. Esseltine, A. Hui, K. Venkatakrishnan, 2015, British journal of clinical pharmacology.

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy : analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

D. Esseltine, M. Dimopoulos, A. Palumbo, 2010 .

Long term follow-up of PAD for untreated multiple myeloma

D. Esseltine, J. Cavenagh, N. Curry, 2007 .